PER
Click for more information
4.94% 8.5¢ percheron therapeutics limited

Sarepta FDA meeting 3rd Q 2024 is in reference to the PPMO drug...

  1. Akki
    35,674 Posts.
    lightbulb Created with Sketch. 548
    clock Created with Sketch.
    03/02/24
    23:52
    Post #: 72224398
    Sarepta FDA meeting 3rd Q 2024 is in reference to the PPMO drug 5501 with data recently released.

    Elevidys gene therapy expanded label response from FDA is next month.
    PER Price at posting: 6.0¢ Sentiment: None Disclosure: Held
    Likes Created with Sketch. 4  Upvote
    lightbulb Created with Sketch. 1  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

SVL Silver Mines models five new calderas close to 396Moz Bowdens deposit
right-arrow Created with Sketch.
SXL Southern Cross says no to buy up of Australian Community Media assets
right-arrow Created with Sketch.
PDN Paladin flags up to 4.5Mlbs of uranium production in FY25 guidance
right-arrow Created with Sketch.
TBN Tamboran is developing the NT Beetaloo Basin. To get there, it's listing at $36/sh on the NYSE
right-arrow Created with Sketch.
NIM Nimy extends sulphide targets at Mons with new anomalies identified
right-arrow Created with Sketch.
NEWS Tenant turnover: Reducing costs and revenue-loss
right-arrow Created with Sketch.
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.5¢ 		Change
0.004(4.94%) 		Mkt cap ! $76.63M
Open High Low Value Volume
8.1¢ 8.5¢ 8.1¢ $46.54K 563.7K

Buyers (Bids)

No. Vol. Price($)
2 164616 8.1¢
 

Sellers (Offers)

Price($) Vol. No.
8.5¢ 100110 1
View Market Depth
Last trade - 15.55pm 28/06/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.